Viracta Therapeutics (VIRX)
(Delayed Data from NSDQ)
$0.54 USD
+0.04 (7.64%)
Updated Jul 12, 2024 04:00 PM ET
After-Market: $0.51 -0.03 (-5.20%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth A Momentum C VGM
Income Statements
Fiscal Year end for Viracta Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 0 | 0 | 2 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 0 | 0 | 0 | 2 |
Selling & Adminstrative & Depr. & Amort Expenses | 51 | 51 | 114 | 22 | 25 |
Income After Depreciation & Amortization | -51 | -51 | -114 | -22 | -23 |
Non-Operating Income | 3 | 2 | 0 | 1 | 0 |
Interest Expense | 4 | 1 | 0 | 0 | 1 |
Pretax Income | -51 | -49 | -115 | -22 | -23 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -51 | -49 | -115 | -22 | -23 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -51 | -49 | -115 | -22 | -23 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -52 | -51 | -114 | -22 | -23 |
Depreciation & Amortization (Cash Flow) | -2 | 0 | 0 | 0 | 0 |
Income After Depreciation & Amortization | -51 | -51 | -114 | -22 | -23 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 38.63 | 37.79 | 31.87 | NA | 2.49 |
Diluted EPS Before Non-Recurring Items | -1.32 | -1.30 | 2.00 | NA | -9.45 |
Diluted Net EPS (GAAP) | -1.32 | -1.30 | -3.60 | -5.36 | -9.45 |
Fiscal Year end for Viracta Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | NA | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 13.88 | 13.56 | 12.48 | 12.45 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -13.88 | -13.56 | -12.48 | -12.45 |
Non-Operating Income | NA | 5.59 | 0.75 | 0.83 | 0.89 |
Interest Expense | NA | 0.86 | 0.95 | 0.95 | 0.92 |
Pretax Income | NA | -9.14 | -13.77 | -12.60 | -12.48 |
Income Taxes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -9.14 | -13.77 | -12.60 | -12.48 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -9.14 | -13.77 | -12.60 | -12.48 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | NA | 39.32 | 38.79 | 38.68 | 38.56 |
Diluted EPS Before Non-Recurring Items | NA | -0.23 | -0.35 | -0.33 | -0.32 |
Diluted Net EPS (GAAP) | NA | -0.23 | -0.35 | -0.33 | -0.32 |